Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

Launched by NOVARTIS PHARMACEUTICALS · Mar 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called secukinumab in people with ankylosing spondylitis (AS) who have never used certain types of medications before. The trial is specifically looking for participants between the ages of 18 and 40 who have been diagnosed with AS and are currently experiencing active symptoms. To qualify, participants must meet specific criteria, such as having a BASDAI score of 4 or higher, which indicates the level of their disease activity, and must not have used other treatments like TNFi, JAKi, or IL-17i drugs.

If you or someone you know is interested in participating, this study will last about 28 weeks and involves regular check-ins to monitor symptoms and treatment effects. The trial is not yet recruiting participants, but it aims to gather important information to help understand how well secukinumab works in this specific group of patients. It’s essential for potential participants to be in good health and not have any conditions that would prevent them from completing the study. This research could provide valuable insights for future treatments of ankylosing spondylitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
• • 2. Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4
• • 3. Subjects who have never used TNFi, JAKi, or IL-17i drugs before
• • 4. Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
• • 5. Subjects who have a time of less than 5 years since AS diagnosis
• • 6. Subjects who are above the age of 18 years and below 40years old
• • 7. Subjects who give informed consent form to participate in the study
• Exclusion Criteria:
• • 1. Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
• • 2. Subjects who have congenital/traumatic spinal deformities
• • 3. Subjects currently enrolled in other clinical studies
• • 4. Subjects who have any contraindications to secukinumab treatment